Humana Reports Q1 Adjusted EPS Beat, Cuts Full-Year GAAP EPS Guidance

summarizeSummary

Humana reported Q1 Adjusted EPS of $10.31, beating estimates, but revised its full-year GAAP EPS guidance downwards to 'at least $8.36' from 'at least $8.89', while affirming its Adjusted EPS guidance and Medicare Advantage growth targets.

check_boxKey Events

• Q1 Adjusted EPS Exceeds Estimates

  Humana reported first-quarter 2026 Adjusted EPS of $10.31, surpassing analyst estimates of $10.19. GAAP EPS for the quarter was $9.83.

• Full-Year GAAP EPS Guidance Reduced

  The company revised its full-year 2026 GAAP EPS guidance downwards to 'at least $8.36' from its previous estimate of 'at least $8.89'.

• Full-Year Adjusted EPS Guidance Affirmed

  Humana affirmed its full-year 2026 Adjusted EPS guidance of 'at least $9.00', indicating confidence in its operational performance despite the GAAP revision.

• Medicare Advantage Growth Affirmed

  The company reiterated its expectation for approximately 25% individual Medicare Advantage membership growth in 2026, driven by new sales and improved retention.

auto_awesomeAnalysis

Humana reported mixed first-quarter results, with Adjusted EPS exceeding analyst estimates but a notable reduction in its full-year GAAP EPS guidance. The company affirmed its full-year Adjusted EPS guidance and Medicare Advantage membership growth expectations, indicating operational stability despite the GAAP revision. The GAAP guidance cut, from 'at least $8.89' to 'at least $8.36', is a significant negative signal, likely reflecting ongoing challenges such as the previously disclosed Star Ratings headwind for Bonus Year 2026. Investors should monitor the company's ability to mitigate these headwinds and achieve its affirmed Adjusted EPS targets, as well as the impact of the leadership transition in its Insurance segment.